Inherited thrombophilia, pregnancy, and oral contraceptive use: Clinical implications

Seminars in Vascular Medicine

Volumn 3, Issue 1, 2003, Pages 47-59

  De Stefano, Valerio ^a   Rossi, Elena ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Fetal loss; Inherited thrombophilia; Obstetric complications; Oral contraceptives; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ANTITHROMBIN III DEFICIENCY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; FEMALE; FETUS WASTAGE; HEREDITY; HIGH RISK PATIENT; HOMOZYGOSITY; HORMONE SUBSTITUTION; HUMAN; INHERITANCE; INTRAUTERINE GROWTH RETARDATION; MENOPAUSE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SOLUTIO PLACENTAE; TERATOGENICITY; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0042884399     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38332     Document Type: Review

References (96)

1. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thomb Haemost 1996;76:651-662
2. Jordan FLJ, Nandorff A. The familial tendency in thromboembolic disease. Acta Med Scand 1956;156:267-275
3. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-530
4. Griffin J, Evatt B, Zimmerman T, Kleiss A, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373
5. Comp P, Esmon C. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984;311:1525-1528
6. Schwarz HP, Fischer M, Hopmeier P, Batard M, Griffin J. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-1300
7. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544
8. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008
9. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506
10. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
12. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998;24:367-379
13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
14. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708
15. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173
16. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-160
17. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151:933-938
18. Andersen BS, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium. An 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998;77:170-173
19. Mc Coll MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-1188
20. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619
21. Ray JC, Chan WS. Deep vein thrombosis during pregnancy and puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999;54:265-271
22. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methyl-enetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998;179:1324-1328
23. Martinelli I, De Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87:791-795
24. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-380
25. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990;63:319-320
26. De Stefano V, Leone G, Mastrangelo S, Tripodi A, et al. Thrombosis during pregnancy and surgery, in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994;71:799-800
27. Vicente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. Am J Hematol 1994;46:151-152
28. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-748
29. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996;125:955-960
30. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997;176:883-886
31. Lindqvist PG, Svensson PJ, Marsaal K, et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999;81:532-537
32. Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000;20:266-270
33. De Stefano V, Mastrangelo S, Paciaroni K, et al. Thrombotic risk during pregnancy and puerperium in women with APC-resistance. Effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995;74:793-794
34. Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92:473-478
35. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996;131:1145-1148
36. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997;176:889-893
37. McColl MD, Ellison J, Reid F, et al. Prothrombin 20210 G→A, MTHF C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 2000;107:565-569
38. Martinelli I, Legnani C, Bucciarelli P, et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-803
39. Middeldorp S, Libourel E, Hamulyak K, van der Meer J, Buller H. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001;113:553-555
40. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clots in This Pregnancy Study Group. N Engl J Med 2000;343:1439-1444
41. Abildgaard U, Viskjold F, Majak P. Hereditary antithrombin deficiency and pregnancy: venous thromboembolism despite prophylaxis with LMW heparin. Thromb Haemost 2001; Suppl. Abst P1470
42. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982;14:127-141
43. De Stefano V, Leone G, De Carolis S, et al. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988;59:193-196
44. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13
45. Dovey DA, MacGillivray I. The classification and definition of hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892-898
46. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167
47. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460-465
48. Kupferminc MJ, Fait G, Many A, et al. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000;96:45-49
49. De Groot CJM, Bloemenkamp KWM, Duvekot EJ, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999;181:975-980
50. Dizon-Towson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-905
51. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-1054
52. Krauss T, Augustin HG, Osmers R, et al. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998;92:457-460
53. Nagy B, Toth T, Rigo J Jr, et al. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet 1998;53:478-481
54. van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999;180:1146-1150
55. Grandone E, Margaglione M, Colaizzo D, et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Hemost 1999;81:349-352
56. O'Shaughnessy KM, Fu B, Ferraro F, et al. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999;33:1338-1341
57. Livingston JC, Barton JR, Park V, et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:153-157
58. Ventura SJ, Taffel SM, Mosher WD. Estimates of pregnancies and pregnancy rates for the United States, 1976-85. Am J Public Health 1988;78:506-511
59. Stirrat GM. Recurrent miscarriage. I. Definition and epidemiology. Lancet 1990;336:673-675
60. Samueloff A, Xenakis EM, Berkus MD, Huff RW, Langer O. Recurrent stillbirth: significance and characteristics. J Reprod Med 1993;38:883-886
61. 5). Thromb Haemost 1999;81:891-899
62. Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999;82:634-640
63. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916
64. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996;75:387-388
65. Gris JC, Ripart-Neveu S, Maugard C, et al. Retrospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997;77:1096-1103
66. Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-739
67. Tormene D, Simioni P, Prandoni P, et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999;82:1237-1239
68. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-824
69. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998;128:1000-1003
70. Brenner B, Sarig G, Weiner Z, et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999;82:6-9
71. Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999;14:2448-2450
72. Foka ZJ, Lambropoulos AF, Saravelos H, et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000;15:458-462
73. Younis JS, Brenner B, Ohel G, et al. Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000;43:31-35
74. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000;343:1015-1018
75. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 2000;74:987-991
76. Kupferminc MJ, Peri H, Zwang E, et al. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000;79:963-967
77. Martinelli P, Grandone E, Colaizzo D, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 2001;86:428-431
78. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998;179:1565-1567
79. Younis JS, Ohel G, Brenner B, et al. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000;107:415-419
80. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000;83:693-697
81. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Medical progress: oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535
82. Kemmeren JK, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-9
83. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting factors. Arch Intern Med 2000;160:49-52
84. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994;71:548-552
85. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
86. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596
87. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:28-31
88. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-703
89. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000;5:105-112
90. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816
91. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 2001;86:965-971
92. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996;93:487-490
93. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238
94. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-1797
95. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001;86:112-123
96. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-967